BriaCell Therapeutics Corp. (TSX: BCT)
BCT trades on the Toronto Stock Exchange in Life Sciences, headquartered in British Columbia. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Close · October 14, 2026
C$5.25
-1.13% on the day
Market cap (C$)
C$53.1M
TMX list, September 30, 2026
Market cap (US$)
US$37.2M
Nano cap at 1.4263 C$/US$
1-year return
-69.4%
-46.4% year to date
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of September 30, 2026. US$ figures convert C$ at 1.4263 C$ per US$, the Bank of Canada daily rate for October 14, 2026. Close and returns: Yahoo Finance daily closes for BCT.TO, last bar 2026-10-14, computed by Sophia Capital.
Profile
| Field | Value |
|---|---|
| Ticker | BCT on the Toronto Stock Exchange |
| Yahoo symbol | BCT.TO |
| Sector | Life Sciences |
| Headquarters | British Columbia |
| Listed | 2021-12-31 |
| Listing type | TSXV Grad |
| Shares outstanding | 8,699,787 |
| Also listed on | NasdaqCM |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001610820 |
| Website | No company website on record |
| US listing | BCTX |
Returns
| Window | Return |
|---|---|
| 1 day | -1.1% |
| 1 week | -7.9% |
| 1 month | +5.4% |
| 3 months | +0.6% |
| 6 months | -16.3% |
| Year to date | -46.4% |
| 1 year | -69.4% |
| From 52-week high | -72.6% |
| 52-week range | C$3.80 to C$19.16 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
190 documents in 11 types. Each title links to the document at its source.
Annual financial statements (2)
| Document | Type | Filed |
|---|---|---|
| BriaPro Therapeutics Corp. Consolidated Financial Statements for the period ended July 31, 2025. Period 2025-07-31 | Annual financial statements (8-K) | 2025-12-01 |
| BriaPro Therapeutics Corp. Consolidated Financial Statements for the period ended July 31, 2024. Period 2024-07-31 | Annual financial statements (8-K) | 2024-11-01 |
Interim financial statements (6)
| Document | Type | Filed |
|---|---|---|
| BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three and nine month period ended April 30, 2026. Period 2026-04-30 | Interim financial statements (8-K) | 2026-06-26 |
| BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three and six month period ended January 31, 2026. Period 2026-01-31 | Interim financial statements (8-K) | 2026-03-31 |
| BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three month period ended October 31, 2025. Period 2025-10-31 | Interim financial statements (8-K) | 2025-12-29 |
| BriaPro Therapeutics Corp. Unaudited Condensed interim consolidated financial statements for the three and nine month period ended April 30, 2025. Period 2025-04-30 | Interim financial statements (8-K) | 2025-06-18 |
MD&A (7)
| Document | Type | Filed |
|---|---|---|
| BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the period ended July 31, 2025. Period 2025-07-31 | MD&A (annual) (8-K) | 2025-12-01 |
| BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three month period ended October 31, 2024. Period 2024-10-31 | MD&A (annual) (8-K) | 2024-12-16 |
| BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the period ended July 31, 2024. Period 2024-07-31 | MD&A (annual) (8-K) | 2024-11-01 |
| BriaPro Therapeutics Corp. Management’s Discussion and Analysis for the three and nine month period ended April 30, 2026. Period 2026-04-30 | MD&A (interim) (8-K) | 2026-06-26 |
News release (19)
| Document | Type | Filed |
|---|---|---|
| Pricing Press Release dated May 31, 2026 | News release (8-K) | 2026-06-03 |
| Closing Press Release dated June 2, 2026 | News release (8-K) | 2026-06-03 |
| Press Release dated February 18, 2026 | News release (8-K) | 2026-02-20 |
| Press Release dated January 13, 2026 | News release (8-K) | 2026-01-15 |
Management information circular / proxy (3)
| Document | Type | Filed |
|---|---|---|
| DEF 14A | Proxy statement (DEF 14A) | 2026-02-12 |
| DEFA14A formdefa14a.htm | Proxy statement (DEFA14A) | 2025-01-03 |
| DEF 14A formdef14a.htm | Proxy statement (DEF 14A) | 2024-12-17 |
Prospectus (15)
| Document | Type | Filed |
|---|---|---|
| 424B5 | Prospectus supplement (424B5) | 2026-06-02 |
| 424B4 | Prospectus supplement (424B4) | 2026-01-14 |
| 424B4 | Prospectus supplement (424B4) | 2025-07-16 |
| 424B4 form424b4.htm | Prospectus supplement (424B4) | 2025-04-28 |
Annual report (3)
| Document | Type | Filed |
|---|---|---|
| 10-K Period 2025-07-31 | Annual report (10-K) (10-K) | 2025-10-16 |
| 10-K form10-k.htm Period 2024-07-31 | Annual report (10-K) (10-K) | 2024-10-29 |
| (incorporated by reference to Exhibit 21.1 to our Annual Report on Form 10-K filed with the sec on October 29, 2024) Period 2025-07-31 | Annual report to shareholders (10-K) | 2025-10-16 |
Quarterly report (6)
| Document | Type | Filed |
|---|---|---|
| 10-Q Period 2026-04-30 | Quarterly report (10-Q) (10-Q) | 2026-06-09 |
| 10-Q Period 2026-01-31 | Quarterly report (10-Q) (10-Q) | 2026-03-10 |
| 10-Q Period 2025-10-31 | Quarterly report (10-Q) (10-Q) | 2025-12-11 |
| 10-Q Period 2025-04-30 | Quarterly report (10-Q) (10-Q) | 2025-06-16 |
Early warning / ownership (13)
| Document | Type | Filed |
|---|---|---|
| Schedule 13D amendment | Schedule 13D (SC 13D/A) | 2024-12-12 |
| Schedule 13D amendment | Schedule 13D (SC 13D/A) | 2024-12-10 |
| Schedule 13D amendment | Schedule 13D (SC 13D/A) | 2024-12-05 |
| Schedule 13G | Schedule 13G (SCHEDULE 13G) | 2026-01-23 |
Certification (32)
| Document | Type | Filed |
|---|---|---|
| EX-31.1 Period 2026-04-30 | Certification (SOX 302/906) (10-Q) | 2026-06-09 |
| EX-31.2 Period 2026-04-30 | Certification (SOX 302/906) (10-Q) | 2026-06-09 |
| EX-32.1 Period 2026-04-30 | Certification (SOX 302/906) (10-Q) | 2026-06-09 |
| EX-32.2 Period 2026-04-30 | Certification (SOX 302/906) (10-Q) | 2026-06-09 |
Other (84)
| Document | Type | Filed |
|---|---|---|
| 8-K | Current report (8-K) (8-K) | 2026-06-26 |
| 8-K | Current report (8-K) (8-K) | 2026-06-03 |
| 8-K | Current report (8-K) (8-K) | 2026-03-31 |
| 8-K | Current report (8-K) (8-K) | 2026-03-09 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
Trading: the last notice, on 2025-07-15, was a resumption.
| Notice | Action | Reason | Notice |
|---|---|---|---|
| 2025-07-15 3:30 PM ET | Resumption | No reason stated | CIRO notice |
| 2025-07-15 3:10 PM ET | Halt | Dissemination | CIRO notice |
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2021-06-15 | Equity, Option To Acquire, Security To Be Acquired | US$27.2M | US$27.2M | SEC EDGAR |
| 2018-04-10 | Debt, Option To Acquire, Security To Be Acquired | US$800K | US$800K | SEC EDGAR |
| 2014-12-12 | Equity, Option To Acquire, Security To Be Acquired, Other | US$6.0M | US$6.0M | SEC EDGAR |
| 2014-06-20 | Equity, Option To Acquire, Security To Be Acquired, Other | US$299K | US$881K | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| MIR | MedMira Inc. | TSXV | C$53.1M | 0.0% | -30.0% |
| ZYUS | ZYUS Life Sciences Corporation | TSXV | C$48.3M | +11.1% | -20.6% |
| NTLX | Neurothera Labs Inc. | TSXV | C$60.4M | -47.6% | +9.5% |
| ARCH | Arch Biopartners Inc. | TSXV | C$60.5M | -10.8% | -24.5% |
| WOLF | Grey Wolf Health Corp. | TSXV | C$60.6M | +2.4% | +28.9% |
The app has the price chart, every filing, private raises and the full peer set for BCT.
Open in the app